• About
• Links
• Contact
• Sitemap

Sitemap > Breaking Research > Oncology

• Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients.
• Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase.
• Inhibitor of p42/44 mitogen-activated protein kinase, but not p38 MAPK, attenuated antigen challenge of guinea pig airways in vitro.
• Preparation of novel aza-1,7-annulated indoles and their conversion to potent indolocarbazole kinase inhibitors.
• Analogs of sub-nanomolar hMC1R agonist LK-184 [Ph(CH2)3CO-His-D-Phe-Arg-Trp-NH2]. An additional binding site within the human melanocortin receptor 1?
• Aptamer selection for the inhibition of cell adhesion with fibronectin as target.
• Synthesis of potent taxoids for tumor-specific delivery using monoclonal antibodies.
• Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.
• Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.
• Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study.
• Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports.
• Inhibition of papilloma progression by antisense oligonucleotides targeted to HPV11 E6/E7 RNA.
• Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
• Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists.
• Differences in gene expression between B-cell chronic lymphocytic leukemia and normal B cells: a meta-analysis of three microarray studies.
• Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.
• BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
• Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase.
• Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer.
• Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors.
• Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo.
• Fungal polysaccharopeptide inhibits tumor angiogenesis and tumor growth in mice.
• Noninvasive delivery of small inhibitory RNA and other reagents to pulmonary alveoli in mice.
• A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma.
• Jak kinase activity is required for lymphoma invasion and metastasis.
• SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.
• Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo.
• Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens.
• Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis.
• N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2.
• Synthesis and antitumor activity of quinonoid derivatives of cannabinoids.
• Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction.
• Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
• Prevalence of irritable bowel syndrome: a community survey.
• The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition.
• Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12.
• Gabexate mesilate inhibits colon cancer growth, invasion, and metastasis by reducing matrix metalloproteinases and angiogenesis.
• Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
• Antisense protein kinase A RIalpha inhibits 7,12-dimethylbenz(a)anthracene-induction of mammary cancer: blockade at the initial phase of carcinogenesis.
• Blockade of allergic airway inflammation following systemic treatment with a B7-dendritic cell (PD-L2) cross-linking human antibody.
• Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
• Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects.
• Is interleukin-13 critical in maintaining airway hyperresponsiveness in allergen-challenged mice?
• Thromboxane A2 receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration.
• Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma.
• Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.
• Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts.
• Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer.
• A QSAR study on inhibitory activities of 1-phenylbenzimidazoles against the platelet-derived growth factor receptor.
• Effect of oral CCK-1 agonist GI181771X on fasting and postprandial gastric functions in healthy volunteers.
• Prostasin, a membrane-anchored serine peptidase, regulates sodium currents in JME/CF15 cells, a cystic fibrosis airway epithelial cell line.
• Total deletion of in vivo telomere elongation capacity: an ambitious but possibly ultimate cure for all age-related human cancers.
• Novel immunosuppressive properties of interleukin-6 in dendritic cells: inhibition of NF-kappaB binding activity and CCR7 expression.
• Identification of metastasis-related genes in a mouse model using a library of randomized ribozymes.
• A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis.
• Does concomitant stress incontinence alter the efficacy of tolterodine in patients with overactive bladder?
• Effects of alpha 1-adrenergic receptor subtype selective antagonists on lower urinary tract function in rats with bladder outlet obstruction.
• Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract.
• Oral administration of desloratadine prior to sensitization prevents allergen-induced airway inflammation and hyper-reactivity in mice.
• Contribution of the p38MAPK signalling pathway to proliferation in human cultured airway smooth muscle cells is mitogen-specific.
• Asthma as a risk factor for COPD in a longitudinal study.
• Airway mucosal thickening and bronchial hyperresponsiveness induced by inhaled beta 2-agonist in mice.
• Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.
• Development of a cancer DNA phenotype prior to tumor formation.
• A rare-cell detector for cancer.
• Development of a chimaeric receptor approach to study signalling by tumour necrosis factor receptor family members.
• Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling.
• Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC).
• Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group.
• Inhibition of poly(ADP-ribose) polymerase prevents allergen-induced asthma-like reaction in sensitized Guinea pigs.
• Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue.
• Analysis of FDA approved anticancer drugs reveals the future of cancer therapy.
• Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility.
• Apolipoprotein A-IV inhibits experimental colitis.
• Inhibition of experimental asthma by indoleamine 2,3-dioxygenase.
• Regulation of pulmonary fibrosis by chemokine receptor CXCR3.
• Adult Asthma Consensus Guidelines Update 2003.
• DFU, a selective COX-2 inhibitor, suppresses MCF-7 xenograft tumor growth in mice.
• Reduced intestinal inflammation induced by dextran sodium sulfate in interleukin-6-deficient mice.
• Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models.
• Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin.
• Systemic administration of serotonin 2A/2C agonist improves upper airway stability in Zucker rats.
• Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer.
• Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts.
• Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and anti-telomerase short-interfering RNA.
• Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo.
• A specific antagonist of the p110delta catalytic component of phosphatidylinositol 3'-kinase, IC486068, enhances radiation-induced tumor vascular destruction.
• High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus.
• AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
• BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.
• Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein MRP1.
• Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells.
• Immunotherapeutic potential of B7-DC (PD-L2) cross-linking antibody in conferring antitumor immunity.
• Overriding imatinib resistance with a novel ABL kinase inhibitor.
• The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients.
• 15-Lipoxygenase-2 expression in benign and neoplastic lung: an immunohistochemical study and correlation with tumor grade and proliferation.
• Pergolide mesylate can improve sexual dysfunction in patients with Parkinson's disease: the results of an open, prospective, 6-month follow-up.
• Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors.
• Aminotriazine 5-HT7 antagonists.
• Diaminopyrimidine and diaminopyridine 5-HT7 ligands.
• Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine.
• Elevation of intracavernous pressure and NO-cGMP activity by a new herbal formula in penile tissues of aged and diabetic rats.
• Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action.
• The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency.
• Insulin-like growth factor 1 stimulates KCl cotransport, which is necessary for invasion and proliferation of cervical cancer and ovarian cancer cells.
• The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial.
• Potent histone deacetylase inhibitors: N-hydroxybenzamides with antitumor activities.
• Heparin normalizes allergen-induced nitric oxide deficiency and airway hyperresponsiveness.
• Matrix metalloproteinase expression and activity in human airway smooth muscle cells.
• Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis.
• Protective role of arginase in a mouse model of colitis.
• Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer.
• An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate epithelium.
• Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer.
• Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.
• Novel 2-aminotetralin and 3-aminochroman derivatives as selective serotonin 5-HT7 receptor agonists and antagonists.
• Design, synthesis, and structure-activity relationship studies of 3,4,6-triphenylpyran-2-ones as selective cyclooxygenase-2 inhibitors.
• Synthesis and aromatase inhibitory activity of novel pyridine-containing isoflavones.
• Discovery of the pyrrolo[2,1-f][1,2,4]triazine nucleus as a new kinase inhibitor template.
• The cooperative prostate cancer tissue resource: a specimen and data resource for cancer researchers.
• Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial.
• Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
• A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor.
• Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses.
• A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma.
• Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
• The new NICE guidelines on COPD.
• Adenovirus expressing Fas ligand gene decreases airway hyper-responsiveness and eosinophilia in a murine model of asthma.
• Long-term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (OMNICONTROL study): first-year follow-up report.
• Reversal of established CD4+ type 2 T helper-mediated allergic airway inflammation and eosinophilia by therapeutic treatment with DNA vaccines limits progression towards chronic inflammation and remodelling.
• Neurokinin-1 receptor mediates stress-exacerbated allergic airway inflammation and airway hyperresponsiveness in mice.
• Phosphodiesterase type IV inhibitors prevent ischemia-reperfusion-induced gastric injury in rats.
• Role of p16/INK4a in gastrointestinal stromal tumor progression.
• Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease.
• Simultaneous treatment of asthma and allergic rhinitis.
• A microplate assay for selective measurement of growth of epithelial tumor cells in direct coculture with stromal cells.
• Synthesis and multidrug resistance reversal activity of 1,2-disubstituted tetrahydroisoquinoline derivatives.
• Selective induction of G2/M arrest and apoptosis in HL-60 by a potent anticancer agent, HMJ-38.
• Retinoids and cancer: antitumor effect of ATRA and of a new derivative of retinoic acid, IIF, on colon carcinoma cell lines CaCo-2 and HT-29.
• Epoetin beta (NeoRecormon) corrects anaemia in patients with hormone-refractory prostate cancer and bone metastases.
• The effects of early or late neurolytic sympathetic plexus block on the management of abdominal or pelvic cancer pain.
• Synthesis, crystal structure and cytotoxicity of new oxaliplatin analogues indicating that improvement of anticancer activity is still possible.
• A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors.
• A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors.
• Inhibition of tumor cell proliferation by sigma ligands is associated with K+ Channel inhibition and p27kip1 accumulation.
• Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis.
• Protein kinase Cdelta mediates lysophosphatidic acid-induced NF-kappaB activation and interleukin-8 secretion in human bronchial epithelial cells.
• NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy.
• A proteomic approach for the discovery of protease substrates.
• Prospects for total synthesis: a vision for a totally synthetic vaccine targeting epithelial tumors.
• Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas.
• Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.
• The development of emphysema in cigarette smoke-exposed mice is strain dependent.
• PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase.
• Experimental Peptide Identification Repository (EPIR): an integrated peptide-centric platform for validation and mining of tandem mass spectrometry data.
• Cancer cachexia is regulated by selective targeting of skeletal muscle gene products.
• Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis.
• Novel 2'-substituted, 3'-deoxy-phosphatidyl-myo-inositol analogues reduce drug resistance in human leukaemia cell lines with an activated phosphoinositide 3-kinase/Akt pathway.
• In vitro and in vivo evaluation of a melamine dendrimer as a vehicle for drug delivery.
• Preclinical characterisation of 111In-DTPA-trastuzumab.
• A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalcemia.
• An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth.
• Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
• PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism.
• A new strategy to block tumor growth by inhibiting endocannabinoid inactivation.
• ZD9331 as second- or third-line therapy in patients with advanced colorectal cancer: a phase II multicenter trial.
• beta-agonists through metered-dose inhaler with valved holding chamber versus nebulizer for acute exacerbation of wheezing or asthma in children under 5 years of age: a systematic review with meta-analysis.
• A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
• Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
• Direct effects of 9-anthracene compounds on cystic fibrosis transmembrane conductance regulator gating.
• Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials.
• Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis.
• Protection of transplant-induced renal ischemia-reperfusion injury with carbon monoxide.
• Re-expression of detachment-inducible chloride channel mCLCA5 suppresses growth of metastatic breast cancer cells.
• Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.
• A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.
• Efficacy and tolerability of manidipine in the treatment of hypertension in patients with non-diabetic chronic kidney disease without glomerular disease. Prospective, randomized, double-blind study of parallel groups in comparison with enalapril.
• PPAR-gamma agonists as therapy for diseases involving airway neutrophilia.
• Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site.
• Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase.
• Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents.
• 2-(1-adamantyl)-4-(thio)chromenone-6-carboxylic acids: potent reversible inhibitors of human steroid sulfatase.
• IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer.
• A novel TARP-promoter-based adenovirus against hormone-dependent and hormone-refractory prostate cancer.
• The treatment with a COX-2 specific inhibitor is effective in the management of pain related to endometriosis.
• Reversal of P-glycoprotein-mediated multidrug resistance by Alisol B 23-acetate.
• Lysosomal phospholipase A2 is selectively expressed in alveolar macrophages.
• pH-triggered microparticles for peptide vaccination.
• Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment.
• Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with diabetes mellitus induced by streptozotocin.
• A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine.
• A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
• Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells.
• Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies.
• Antitumor activity of systemically delivered ribozymes targeting murine telomerase RNA.
• Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.
• Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer.
• Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.
• A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
• Small interfering RNA-induced transcriptional gene silencing in human cells.
• Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital.
• Resiquimod, a new immune response modifier from the family of imidazoquinolinamines, inhibits allergen-induced Th2 responses, airway inflammation and airway hyper-reactivity in mice.
• Antitumor activity of pyrvinium pamoate, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methyl-quinolinium pamoate salt, showing preferential cytotoxicity during glucose starvation.
• Airway injury in lung disease pathophysiology: selective depletion of airway stem and progenitor cell pools potentiates lung inflammation and alveolar dysfunction.
• Estrogen regulates pulmonary alveolar formation, loss, and regeneration in mice.
• Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer.
• Transient adenoviral N-methylpurine DNA glycosylase overexpression imparts chemotherapeutic sensitivity to human breast cancer cells.
• Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody.
• Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model.
• Inhibition of alpha5 integrin decreases PI3K activation and cell adhesion of human colon cancers.
• Employing tumor hypoxia to enhance oncolytic viral therapy in breast cancer.
• Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer.
• A simple method to cure established tumors by inflammatory killing of normal cells.
• Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer.
• Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial.
• Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
• Outcomes and cost of deep venous thrombosis among patients with cancer.
• In vitro and in vivo characterization of a novel naphthylamide ATP-sensitive K+ channel opener, A-151892.
• Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
• A vascular cell-restricted RhoGAP, p73RhoGAP, is a key regulator of angiogenesis.
• Inhibition of endothelial cell proliferation by targeting Rac1 GTPase with small interference RNA in tumor cells.
• A novel pyrazolone, 4,4-dichloro-1-(2,4-dichlorophenyl)-3-methyl-5-pyrazolone, as a potent catalytic inhibitor of human telomerase.
• Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.
• Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970.
• In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model.
• Molecular dissection of the butyrate action revealed the involvement of mitogen-activated protein kinase in cystic fibrosis transmembrane conductance regulator biogenesis.
• A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent.
• Impairment of the antiproliferative effect of glucocorticosteroids by 11beta-hydroxysteroid dehydrogenase type 2 overexpression in MCF-7 breast-cancer cells.
• Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
• Nitrosulindac (NCX 1102): a new nitric oxide-donating non-steroidal anti-inflammatory drug (NO-NSAID), inhibits proliferation and induces apoptosis in human prostatic epithelial cell lines.
• Activation of the orphan nuclear receptor RORalpha counteracts the proliferative effect of fatty acids on prostate cancer cells: crucial role of 5-lipoxygenase.
• The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma.
• Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin.
• Barriers to effective cancer pain management: a survey of Australian family caregivers.
• Octreotide LAR resolves severe chemotherapy-induced diarrhoea (CID) and allows continuation of full-dose therapy.
• Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC).
• Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window.
• Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction.
• Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer.
• Intracavernosal injection of vascular endothelial growth factor improves erectile function in aged rats.
• Antitussive effect of NS-398, a selective cyclooxygenase-2 inhibitor, in guinea pigs.
• Immunostimulatory oligonucleotides attenuate airways remodeling in allergic monkeys.
• Effects of anticytokine therapy in a mouse model of chronic asthma.
• The role of virus-specific immunoglobulin E in airway hyperresponsiveness.
• T-bet upregulation and subsequent interleukin 12 stimulation are essential for induction of Th1 mediated immunopathology in Crohn's disease.
• Rofecoxib decreases renal injury in obese Zucker rats.
• Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
• Identification of a novel integrin alphavbeta3 binding site in CCN1 (CYR61) critical for pro-angiogenic activities in vascular endothelial cells.
• Abnormal gene expression profiles in human ovaries from polycystic ovary syndrome patients.
• Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo.
• Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors.
• Long-term protection of obese Zucker rat kidneys from fibrosis and renal failure with an angiotensin-converting enzyme inhibitor/diuretic combination.
• FR167653 reduces obliterative airway disease in rats.
• Poly (ADP) ribose synthetase inhibition reduces obliterative airway disease in rat tracheal allografts.
• Phosphodiesterase inhibitors as anti-cancer drugs.
• Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor.
• Protein kinase C alpha/beta inhibitor Go6976 promotes formation of cell junctions and inhibits invasion of urinary bladder carcinoma cells.
• CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells.
• Pathophysiological effects of vascular endothelial growth factor receptor-2-blocking antibody plus fractionated radiotherapy on murine mammary tumors.
• Antisense targeting protein kinase C alpha and beta1 inhibits gastric carcinogenesis.
• Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia.
• Discovery of an allosteric site in the caspases.
• 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
• Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma.
• Inhibition of signal transducer and activator of transcription 1 attenuates allergen-induced airway inflammation and hyperreactivity.
• alpha-Lipoic acid inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma.
• Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093).
• Alpha1-antitrypsin inhibits angiogenesis and tumor growth.
• Determinants of retinoid X receptor transcriptional antagonism.
• Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer.
• Pharmacological exploitation of the alpha1-adrenoreceptor antagonist doxazosin to develop a novel class of antitumor agents that block intracellular protein kinase B/Akt activation.
• Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors.
• Substituted pyridazino[3,4-b][1,5]benzoxazepin-5(6H)ones as multidrug-resistance modulating agents.
• Circulating tumor cells, disease progression, and survival in metastatic breast cancer.
• The phosphodiesterase III inhibitor olprinone decreases sensitivity of rat Kupffer cells to endotoxin.
• A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
• Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma.
• Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.
• Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia.
• Evaluation of a novel in vitro Caco-2 hepatocyte hybrid system for predicting in vivo oral bioavailability.
• Rational design of RAR-selective ligands revealed by RARbeta crystal stucture.
• Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis.
• Vitamin D receptor-deficient mice fail to develop experimental allergic asthma.
• n-Nonanoyl-CC chemokine ligand 14, a potent CC chemokine ligand 14 analogue that prevents the recruitment of eosinophils in allergic airway inflammation.
• The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer.
• Abnormal TNF activity in Timp3-/- mice leads to chronic hepatic inflammation and failure of liver regeneration.
• Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study.
• Selective Itk inhibitors block T-cell activation and murine lung inflammation.
• Synthesis of 1H-pyridin-2-one derivatives as potent and selective farnesyltransferase inhibitors.
• Synthesis and biological evaluation of stilbene-based pure estrogen antagonists.
• Identification of a potent and rapidly reversible inhibitor of the 20S-proteasome.
• 3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.
• Synthesis and biological evaluation of taxinine analogues as orally active multidrug resistance reversal agents in cancer.
• Design and synthesis of substituted N-methylbenzamide analogues derived from SR 48,968 as neurokinin-2 receptor antagonists.
• PREDICT modeling and in-silico screening for G-protein coupled receptors.
• Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease.
• Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes.
• Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency.
• Protective effects of FTY720 on chronic allograft nephropathy by reducing late lymphocytic infiltration.
• Is decreased libido associated with the use of HMG-CoA-reductase inhibitors?
• Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma.
• A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer.
• Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease.
• A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer.
• Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors.
• CXCR4 and CXCL12 (SDF-1) in prostate cancer: inhibitory effects of human single chain Fv antibodies.
• Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria.
• NF-kappaB functions as a tumour promoter in inflammation-associated cancer.
• TZT-1027 elucidates antitumor activity through direct cytotoxicity and selective blockade of blood supply.
• A phase II trial of weekly paclitaxel and gemcitabine in non-small cell lung cancer patients previously treated with platinum and vinorelbine.
• Near completely humanized liver in mice shows human-type metabolic responses to drugs.
• Activation of the tumor-specific death effector apoptin and its kinase by an N-terminal determinant of simian virus 40 large T antigen.
• Pharmacological study of IQM-97,423, a potent and selective CCK1 receptor antagonist with protective effect in experimental acute pancreatitis.
• Transplantation in the diabetic patient with advanced chronic kidney disease: a task force report.
• Pilot study of the effects of ONO-5046 in patients with acute respiratory distress syndrome.
• Antitussive activity of iodo-resiniferatoxin in guinea pigs.
• Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy.
• A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence.
• Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages.
• Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000.
• Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study.
• Ameliorative effect of IDS 30, a stinging nettle leaf extract, on chronic colitis.
• Thromboxane receptor mediates renal vasoconstriction and contributes to acute renal failure in endotoxemic mice.
• Dipeptidomimetic ketomethylene isosteres as pro-moieties for drug transport via the human intestinal di-/tripeptide transporter hPEPT1: design, synthesis, stability, and biological investigations.
• Identification of 4-piperazin-1-yl-quinazoline template based aryl and benzyl thioureas as potent, selective, and orally bioavailable inhibitors of platelet-derived growth factor (PDGF) receptor.
• Synthesis of benzimidazole based analogues of sphingosine-1-phosphate: discovery of potent, subtype-selective S1P4 receptor agonists.
• Synthesis and evaluation of novel oxazoline MMP inhibitors.
• A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
• XBP1 is essential for survival under hypoxic conditions and is required for tumor growth.
• Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer.
• Angiopoietin-3 inhibits pulmonary metastasis by inhibiting tumor angiogenesis.
• Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion.
• Netrin-1 controls colorectal tumorigenesis by regulating apoptosis.
• Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus.
• A new interferon, limitin, displays equivalent immunomodulatory and antitumor activities without myelosuppressive properties as compared with interferon-alpha.
• The novel histone deacetylase inhibitor BL1521 inhibits proliferation and induces apoptosis in neuroblastoma cells.
• Liver delivery of NO by NCX-1000 protects against acute liver failure and mitochondrial dysfunction induced by APAP in mice.
• A selective androgen receptor modulator for hormonal male contraception.
• Carcinoembryonic antigen directed herpes viral oncolysis improves selectivity and activity in colorectal cancer.
• Role of the renin-angiotensin system in hepatic ischemia reperfusion injury in rats.
• Design, synthesis, and activity of caffeoyl pyrrolidine derivatives as potential gelatinase inhibitors.
• STAT6-mediated signaling in Th2-dependent allergic asthma: critical role for the development of eosinophilia, airway hyper-responsiveness and mucus hypersecretion, distinct from its role in Th2 differentiation.
• The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus.
• A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death.
• Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma.
• Combined effect of arsenic trioxide and sulindac sulfide in A549 human lung cancer cells in vitro.
• Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models.
• Structure-activity relationships of epolactaene derivatives: structural requirements for inhibition of Hsp60 chaperone activity.
• Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.
• 4-Aryl-3-(mercapto)quinolin-2-ones: novel maxi-K channel opening relaxants of corporal smooth muscle.
• Synthetic curcumin analogs inhibit activator protein-1 transcription and tumor-induced angiogenesis.
• The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo.
• Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor.
• CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.
• Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth.
• Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms.
• Involvement of enhanced neurokinin NK3 receptor expression in the severe asthma guinea pig model.
• Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy.
• Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
• Phase II trial of bortezomib for patients with advanced renal cell carcinoma.
• Irritable bowel syndrome medications side effects survey.
• Anti-endotoxin monoclonal antibodies are protective against hepatic ischemia/reperfusion injury in steatotic mice.
• Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer.
• ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.
• Structure-based design of a selective heparanase inhibitor as an antimetastatic agent.
• Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity.
• Muscle-targeted interleukin-12 gene therapy of orthotopic hepatocellular carcinoma in mice using in vivo electrosonoporation.
• Heligmosomoides polygyrus inhibits established colitis in IL-10-deficient mice.
• CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts.
• Synthesis of taxoids with improved cytotoxicity and solubility for use in tumor-specific delivery.
• NMR-driven discovery of benzoylanthranilic acid inhibitors of far upstream element binding protein binding to the human oncogene c-myc promoter.
• A locally active antiinflammatory macrolide (MLD987) for inhalation therapy of asthma.
• Pharmacoeconomic challenges in the management of diabetic nephropathy.
• Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia.
• JunD reduces tumor angiogenesis by protecting cells from oxidative stress.
• Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo.
• VIAF, a conserved inhibitor of apoptosis (IAP)-interacting factor that modulates caspase activation.
• Compared with cyclosporine, ISATX247 significantly prolongs renal-allograft survival in a nonhuman primate model.
• Molecular profiling of benign prostatic hyperplasia using a large scale real-time reverse transcriptase-polymerase chain reaction approach.
• Enhanced sensitivity of bladder cancer cells to cisplatin mediated cytotoxicity and apoptosis in vitro and in vivo by the selective cyclooxygenase-2 inhibitor JTE-522.
• Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and gemcitabine in a human bladder cancer KoTCC-1 model.
• A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients.
• alpha2HS-glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progression.
• The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
• SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
• SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations.
• Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting.
• The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.
• Defining a link with asthma in mice congenitally deficient in eosinophils.
• Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung.
• Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.
• Targeting the inverted CCAAT box 2 in the topoisomerase IIalpha promoter by JH-37, an imidazole-pyrrole polyamide hairpin: design, synthesis, molecular biology, and biophysical studies.
• Synthesis and biological evaluation of 1-benzyl-5-(3-biphenyl-2-yl-propyl)-1H-imidazole as novel farnesyltransferase inhibitor.
• 3-Thio-quinolinone maxi-K openers for the treatment of erectile dysfunction.
• Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors.
• Synthesis and evaluation of 4-triazolylflavans as new aromatase inhibitors.
• Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins.
• Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist.
• Allergic sensitization enhances the contribution of Rho-kinase to airway smooth muscle contraction.
• Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes.
• A distinct "side population" of cells with high drug efflux capacity in human tumor cells.
• Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells.
• Multiple mechanisms of action of ZR2002 in human breast cancer cells: a novel combi-molecule designed to block signaling mediated by the ERB family of oncogenes and to damage genomic DNA.
• Anti-idiotype x anti-CD44 bispecific antibodies inhibit invasion of lymphoid organs by B cell lymphoma.
• Utilizing alpha-fetoprotein expression to enhance oncolytic viral therapy in hepatocellular carcinoma.
• Blockade of airway hyperresponsiveness and inflammation in a murine model of asthma by a prodrug of cysteine, L-2-oxothiazolidine-4-carboxylic acid.
• Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection.
• Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference.
• JTE-522, a selective COX-2 inhibitor, interferes with the growth of lung metastases from colorectal cancer in rats due to inhibition of neovascularization: a vascular cast model study.
• A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts.
• IL-10 gene therapy is therapeutic for dextran sodium sulfate-induced murine colitis.
• Novel RGD-like molecules based on the tyrosine template: design, synthesis, and biological evaluation on isolated integrins alphaVbeta3/alphaIIbbeta3 and in cellular adhesion tests.
• Comparison of vitamin E derivatives alpha-TEA and VES in reduction of mouse mammary tumor burden and metastasis.
• Hepatitis C virus replication in stably transfected HepG2 cells promotes hepatocellular growth and tumorigenesis.
• Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats.
• An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
• Increased expression of transient receptor potential vanilloid-1 in airway nerves of chronic cough.
• Allergen exposure of mouse airways evokes remodeling of both bronchi and large pulmonary vessels.
• Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation.
• A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
• Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
• Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option.
• Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin.
• Kinase inhibition with BAY 43-9006 in renal cell carcinoma.
• Small molecule modulators of endogenous and co-chaperone-stimulated Hsp70 ATPase activity.
• The impact of DeltaG on the oral bioavailability of low bioavailable therapeutic agents.
• Induction of T helper type 1-like regulatory cells that express Foxp3 and protect against airway hyper-reactivity.
• A module map showing conditional activity of expression modules in cancer.
• Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma.
• A phase II trial of FUdR in patients with advanced pancreatic cancer.
• Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings.
• Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.
• Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours.
• Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones.
• Synthesis and biological evaluation of thiazolidine-2,4-dione and 2,4-thione derivatives as inhibitors of translation initiation.
• Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties.
• The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.
• 17beta-Estradiol replacement improves renal function and pathology associated with diabetic nephropathy.
• Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance.
• A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism.
• Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
• Subtype selective substrates for histone deacetylases.
• PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis.
• Ex vivo characterization of XR11576 (MLN576) against ovarian cancer and other solid tumors.
• Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111.
• Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial.
• The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin?
• Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review.
• A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
• Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis.
• Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis.
• Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis.
• Antitumor activities of a novel indolin-2-ketone compound, Z24: more potent inhibition on bFGF-induced angiogenesis and bcl-2 over-expressing cancer cells.
• Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
• Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship.
• Nucleotide analogues containing 2-oxa-bicyclo[2.2.1]heptane and l-alpha-threofuranosyl ring systems: interactions with P2Y receptors.
• Oncogenic action of secreted phospholipase A2 in prostate cancer.
• Suppression of colorectal cancer liver metastasis and extension of survival by expression of apolipoprotein(a) kringles.
• BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
• Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2).
• Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular multidrug resistance.
• Regulated angiogenesis and vascular regression in mice overexpressing vascular endothelial growth factor in airways.
• Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury.
• Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.
• A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.
• Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
• CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion.
• Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis.
• Identification and characterization of the IKKalpha promoter: positive and negative regulation by ETS-1 and p53, respectively.
• CD155/PVR plays a key role in cell motility during tumor cell invasion and migration.
• Isolation of an anti-angiogenic substance from Agaricus blazei Murill: its antitumor and antimetastatic actions.
• The viral protein A238L inhibits cyclooxygenase-2 expression through a nuclear factor of activated T cell-dependent transactivation pathway.
• Bacteriolytic therapy can generate a potent immune response against experimental tumors.
• CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo.
• Expression patterns of potential therapeutic targets in prostate cancer.
• Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
• Selective inhibition of cyclooxygenase (COX)-2 inhibits endothelial cell proliferation by induction of cell cycle arrest.
• Novel therapeutic approach for cancer using four cardiovascular hormones.
• N-acetylcysteine enhances multidrug resistance-associated protein 1 mediated doxorubicin resistance.
• Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis.
• Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib.
• The effect of inducible nitric oxide synthase on postoperative adhesion formation in rats.
• Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity.
• Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
• GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression.
• Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
• A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium.
• A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.
• Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.
• Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes.
• IPL576,092, a novel anti-inflammatory compound, inhibits leukocyte infiltration and changes in lung function in response to allergen challenge.
• Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin.
• Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice.
• The role of endogenous and exogenous AMP in asthma and chronic obstructive pulmonary disease.
• Protein kinase A isozyme switching: eliciting differential cAMP signaling and tumor reversion.
• The erythropoietin-receptor pathway modulates survival of cancer cells.
• Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients.
• Novel 5-HT7 receptor inverse agonists. Synthesis and molecular modeling of arylpiperazine- and 1,2,3,4-tetrahydroisoquinoline-based arylsulfonamides.
• Increased anti-P-glycoprotein activity of baicalein by alkylation on the A ring.
• Identification of neutral 4-O-alkyl quinolone nonpeptide GnRH receptor antagonists.
• Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.
• Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.
• Distinct regulation of cyclooxygenase-2 by interleukin-1beta in normal and endometriotic stromal cells.
• Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP.
• TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling.
• Three-dimensional structure of P-glycoprotein: the transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state.
• Soluble Robo4 receptor inhibits in vivo angiogenesis and endothelial cell migration.
• Inhibition of angiogenesis by growth factor receptor bound protein 2-Src homology 2 domain bound antagonists.
• Translationally controlled tumor protein is a target of tumor reversion.
• Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study.
• Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference.
• Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin.
• A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis.
• Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome.
• Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody.
• Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo.
• Restoration of bone morphogenetic protein receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line TSU-Pr1.
• HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.
• Adeno-associated viral vector-mediated expression of endostatin inhibits tumor growth and metastasis in an orthotropic pancreatic cancer model in hamsters.
• Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.
• Antiangiogenic properties of fibstatin, an extracellular FGF-2-binding polypeptide.
• Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
• Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial.
• Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy.
• Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
• Poly(ADP-ribose) polymerase-1 gene ablation protects mice from ischemic renal injury.
• Stroke risk and tamoxifen therapy for breast cancer.
• Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice.
• Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation.
• Prevention and reversal of renal injury by leptin in a new mouse model of diabetic nephropathy.
• Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo.
• A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy.
• Chlamydocin-hydroxamic acid analogues as histone deacetylase inhibitors.
• Multidrug resistance-1 (MDR-1): a new target for T cell-based immunotherapy.
• Peroxisome proliferator-activated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510.
• The PP2A-associated protein alpha4 is an essential inhibitor of apoptosis.
• Attenuation of acute experimental colitis by preventing NPY Y1 receptor signaling.
• Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.
• In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.
• Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9.
• Improving the toxicity profile of chemotherapy for advanced ovarian cancer: a potential role for CT-2103.
• CPI-0004Na, a new doxorubicin prodrug, reduces growth of 3LL-H61 carcinoma lung metastases in C57BI/6 mice.
• Controlled release of paclitaxel from microemulsion containing PLGA and evaluation of anti-tumor activity in vitro and in vivo.
• Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide.
• Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases.
• Synthesis of small molecule CDC25 phosphatases inhibitors.
• Synthesis and biological evaluation of novel taxoids designed for targeted delivery to tumors.
• Bone cancer pain model in mice: evaluation of pain behavior, bone destruction and morphine sensitivity.
• Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer.
• Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells.
• CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling.
• Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma.
• TNP-470, an angiogenesis inhibitor, attenuates the development of allograft vasculopathy.
• Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells.
• The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers.
• The HIV protease inhibitor ritonavir synergizes with butyrate for induction of apoptotic cell death and mediates expression of heme oxygenase-1 in DLD-1 colon carcinoma cells.
• Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis.
• Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway.
• Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells.
• HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure.
• Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system.
• Chemical adaptor immunotherapy: design, synthesis, and evaluation of novel integrin-targeting devices.
• Studies of targeting and intracellular trafficking of an anti-androgen doxorubicin-formaldehyde conjugate in PC-3 prostate cancer cells bearing androgen receptor-GFP chimera.
• A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.
• Tumor cell targeted gene delivery by adenovirus 5 vectors carrying knobless fibers with antibody-binding domains.
• Aspirin use and mortality from cancer in a prospective cohort study.
• Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
• Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.
• Activity of MDI-301, a novel synthetic retinoid, in xenografts.
• Cloning and sequencing of variable region cDNAs of a novel human monoclonal antibody to carcinoembryonic antigen, and generation of a single chain variable fragmented antibody.
• Gene therapy of prostate xenograft tumors with a p75NTR lipoplex.
• VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.
• Long-acting analogue of vasoactive intestinal peptide, [R15, 20, 21, L17]-VIP-GRR (IK312532), protects rat alveolar L2 cells from the cytotoxicity of cigarette smoke.
• Serendipitous discovery of an unexpected rearrangement leads to two new classes of potential protease inhibitors.
• Heme oxygenase-1 protects human hepatocytes in vitro against warm and cold hypoxia.
• Peripheral benzodiazepine receptor ligands induce apoptosis and cell cycle arrest in human hepatocellular carcinoma cells and enhance chemosensitivity to paclitaxel, docetaxel, doxorubicin and the Bcl-2 inhibitor HA14-1.
• SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
• The regulated long-term delivery of therapeutic proteins by using antigen-specific B lymphocytes.
• Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype.
• A novel in vitro system, the integrated discrete multiple organ cell culture (IdMOC) system, for the evaluation of human drug toxicity: comparative cytotoxicity of tamoxifen towards normal human cells from five major organs and MCF-7 adenocarcinoma breast cancer cells.
• Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents.
• Novel inhibitors targeted to methionine aminopeptidase 2 (MetAP2) strongly inhibit the growth of cancers in xenografted nude model.
• YC-1 [3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl Indazole] exhibits a novel antiproliferative effect and arrests the cell cycle in G0-G1 in human hepatocellular carcinoma cells.
• Cutting edge: human eosinophils regulate T cell subset selection through indoleamine 2,3-dioxygenase.
• Rescuing melanoma epitope-specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunotherapy.
• Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors.
• An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin.
• A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer.
• Inhibition of the vanilloid receptor subtype-1 attenuates TNBS-colitis.
• Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP.
• Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients.
• Cyclooxygenase-2 expression in deep endometriosis and matched eutopic endometrium.
• Type 5 phosphodiesterase inhibition by sildenafil abrogates acute smoking-induced endothelial dysfunction.
• GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation.
• A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors.
• A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors.
• Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study.
• Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models.
• Therapeutic synergy of oral taxane BMS-275183 and cetuximab versus human tumor xenografts.
• Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toll-like receptor 4.
• Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial.
• A novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen epitope of HER-2.
• Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
• Synthesis of C2-C3'N-linked macrocyclic taxoids. Novel docetaxel analogues with high tubulin activity.
• Ligand discovery using small molecule microarrays.
• Anti-interleukin-12 antibody for active Crohn's disease.
• Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction.
• A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck.
• Tumor necrosis factor-alpha (TNF-alpha) promotes cell survival during spermatogenesis, and this effect can be blocked by infliximab, a TNF-alpha antagonist.
• Zafirlukast treatment for acute asthma: evaluation in a randomized, double-blind, multicenter trial.
• Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years.
• Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.
• Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder.
• Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats.
• Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer.
• Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis.
• Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2.
• Discovery and mechanism of action of a novel series of apoptosis inducers with potential vascular targeting activity.
• Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents.
• Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.
• Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids.
• Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
• Characterization of a population of small macrophages in induced sputum of patients with chronic obstructive pulmonary disease and healthy volunteers.
• 6-[2-(adamantylidene)-hydroxybenzoxazole]-O-sulfamate, a steroid sulfatase inhibitor for the treatment of androgen- and estrogen-dependent diseases.
• American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
• Synergistic effects of Cox-1 and -2 inhibition on bladder and prostate cancer in vitro.
• Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors.
• Structure-based virtual screening and biological evaluation of potent and selective ADAM12 inhibitors.
• Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation.
• 9-cis-retinoic acid analogues with bulky hydrophobic rings: new RXR-selective agonists.
• Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.
• Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model.
• Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer.
• Biological activity of the S-adenosylmethionine decarboxylase inhibitor SAM486A in human breast cancer cells in vitro and in vivo.
• Antibody-mediated transduction of p53 selectively kills cancer cells.
• Theobromine inhibits sensory nerve activation and cough.
• BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells.
• Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study.
• Frontline: Inhibition of allergen-induced pulmonary inflammation by the tripeptide feG: a mimetic of a neuro-endocrine pathway.
• Effect of retinoic acid in experimental diabetic nephropathy.
• HO-1 induction restores c-AMP-dependent lung epithelial fluid transport following severe hemorrhage in rats.
• Ameliorating effect of hepatocyte growth factor on inflammatory bowel disease in a murine model.
• IL-7 exacerbates chronic colitis with expansion of memory IL-7Rhigh CD4+ mucosal T cells in mice.
• Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.
• Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity.
• An orally active matrix metalloproteinase inhibitor, ONO-4817, reduces dextran sulfate sodium-induced colitis in mice.
• Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68).
• Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
• Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model.
• Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, protects against gastric ischemia-reperfusion damage in rats: role of oxygen free radicals generation.
• Preventive effect of Y-27632, a selective Rho-kinase inhibitor, on ischemia/reperfusion-induced acute renal failure in rats.
• Altered airway responsiveness in CD38-deficient mice.
• Syk tyrosine kinase participates in beta1-integrin signaling and inflammatory responses in airway epithelial cells.
• Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice.
• NF-kappa B activation in airways modulates allergic inflammation but not hyperresponsiveness.
• Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy.
• Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity.
• Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.
• Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer.
• Development of late-stage diabetic nephropathy in OVE26 diabetic mice.
• IL-13 may mediate allergen-induced hyperresponsiveness independently of IL-5 or eotaxin by effects on airway smooth muscle.
• Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway.
• Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism.
• New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate cancer chemotherapy.
• Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole.
• An in silico approach to discovering novel inhibitors of human sirtuin type 2.
• Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.
• Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel.
• Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling.
• Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study.
• Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.
• ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas.
• Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer.
• Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.
• Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer.
• Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells.
• Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding.
• Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models.
• Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab.
• Angiostatin directly inhibits human prostate tumor cell invasion by blocking plasminogen binding to its cellular receptor, CD26.
• Ghrelin inhibits FGF-2-mediated angiogenesis in vitro and in vivo.
• Cancer risk in people with epilepsy: the role of antiepileptic drugs.
• 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers.
• 2-(8-Hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl)propionic acid, a small molecule isocoumarin, potentiates dexamethasone-induced apoptosis of human multiple myeloma cells.
• Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors.
• CXCR4 regulates growth of both primary and metastatic breast cancer.
• The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.
• Artificial cell microcapsule for oral delivery of live bacterial cells for therapy: design, preparation, and in-vitro characterization.
• Multi-channel 3-D cell culture device integrated on a silicon chip for anticancer drug sensitivity test.
• Inhibition of IkappaB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo.
• Significance of cyclooxygenase-2 induced via p38 mitogen-activated protein kinase in mechanical stimulus-induced peritoneal adhesion in mice.
• Toll-like receptor 4 or 2 agonists decrease allergic inflammation.
• Animal models for studying respiratory syncytial virus infection and its long term effects on lung function.
• Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma.
• The effect of PDE5 inhibition on the erectile function in streptozotocin-induced diabetic rats.
• Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling.
• Critical role for galectin-3 in airway inflammation and bronchial hyperresponsiveness in a murine model of asthma.
• Modulation of tumor formation and intestinal cell migration by estrogens in the Apc(Min/+) mouse model of colorectal cancer.
• mRNA analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using a real-time quantitative RT-PCR assay.
• Acute renal failure in endotoxemia is dependent on caspase activation.
• Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction.
• Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
• Chemosensitization by erythropoietin through inhibition of the NF-kappaB rescue pathway.
• 17beta-Estradiol upregulates and activates WOX1/WWOXv1 and WOX2/WWOXv2 in vitro: potential role in cancerous progression of breast and prostate to a premetastatic state in vivo.
• Combined radiation therapy and dendritic cell vaccine for treating solid tumors with liver micro-metastasis.
• Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.
• Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).
• Synthesis of the naphthalene-derived inhibitors against Cdc25A dual-specificity protein phosphatase and their biological activity.
• Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties.
• N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.
• Matrix metalloproteinase 11 depletion inhibits cell proliferation in gastric cancer cells.
• Phosphodiesterase inhibition by sildenafil citrate attenuates the learning impairment induced by blockade of cholinergic muscarinic receptors in rats.
• Curcumin stimulates cystic fibrosis transmembrane conductance regulator Cl- channel activity.
• Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells.
• IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML.
• Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study.
• Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients.
• A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma.
• Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs.
• The selective cyclooxygenase-2 inhibitor nimesulide prevents Helicobacter pylori-associated gastric cancer development in a mouse model.
• Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy.
• IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells.
• Phase II study of single-agent pegylated liposomal doxorubicin HCl (PLD) in metastatic breast cancer after first-line treatment failure.
• Novel 2-(substituted phenyl)benzimidazole derivatives with potent activity against IgE, cytokines, and CD23 for the treatment of allergy and asthma.
• Catecholic flavonoids acting as telomerase inhibitors.
• Development of the "Cell Chip": a new in vitro alternative technique for immunotoxicity testing.
• Cyclooxygenase 1 and/or 2 blockade ameliorates the renal tissue damage triggered by ischemia and reperfusion injury.
• Conversion from cyclosporine to tacrolimus after renal transplantation improves cardiovascular risk factors.
• Cyclooxygenase-2 selective inhibitor prevents implantation of eutopic endometrium to ectopic sites in rats.
• Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival.
• Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999.
• A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
• CD40 antisense oligonucleotide inhibition of trinitrobenzene sulphonic acid induced rat colitis.
• FK778 and FK506 combination therapy to control acute rejection after rat liver allotransplantation.
• Imaging progress of herpes simplex virus type 1 thymidine kinase suicide gene therapy in living subjects with positron emission tomography.
• Ero1-L alpha plays a key role in a HIF-1-mediated pathway to improve disulfide bond formation and VEGF secretion under hypoxia: implication for cancer.
• In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy.
• A new immunosuppressant, FTY720, in canine kidney transplantation: effect of single-drug, induction and combination treatments.
• A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors.
• Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells.
• Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft.
• Reduced expression of transforming growth factor beta 1 exacerbates pathology in an experimental asthma model.
• Respiratory syncytial virus-induced exaggeration of allergic airway disease is dependent upon CCR1-associated immune responses.
• Vardenafil provides reliable efficacy over time in men with erectile dysfunction.
• Prevalence of erectile dysfunction among 7689 patients with diabetes or hypertension, or both.
• Apoptotic and autophagic cell death induced by histone deacetylase inhibitors.
• Synchronized infection of cell cultures by magnetically controlled virus.
• Integrin beta1 is required for the invasive behaviour but not proliferation of squamous cell carcinoma cells in vivo.
• Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization.
• Discovery of inhibitors of MCF-7 tumor cell adhesion to endothelial cells and investigation on their mode of action.
• Etodolac, a selective cyclo-oxygenase-2 inhibitor, enhances carboplatin-induced apoptosis of human tongue carcinoma cells by down-regulation of FAP-1 expression.
• CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.
• Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients.
• Inhibitory effect of recombinant adenovirus carrying melittin gene on hepatocellular carcinoma.
• MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate.
• Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer.
• Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.
• Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials.
• Vanilloid receptor 1 antagonists attenuate disease severity in dextran sulphate sodium-induced colitis in mice.
• Membrane fixation of vascular endothelial growth factor receptor 1 ligand-binding domain is important for vasculogenesis and angiogenesis in mice.
• Inhibition of tumor growth in xenografted nude mice with adenovirus-mediated endostatin gene comparison with recombinant endostatin protein.
• The identification and optimization of a N-hydroxy urea series of flap endonuclease 1 inhibitors.
• Synthesis and SAR of novel 4,5-diarylimidazolines as potent P2X7 receptor antagonists.
• Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7.
• 2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion.
• Meta-analysis: The treatment of irritable bowel syndrome.
• Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study.
• A rho kinase inhibitor, Y-27632 inhibits pulmonary eosinophilia, bronchoconstriction and airways hyperresponsiveness in allergic mice.
• Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial.
• Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity.
• The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up.
• BL-1249 [(5,6,7,8-tetrahydro-naphthalen-1-yl)-[2-(1H-tetrazol-5-yl)-phenyl]-amine]: a putative potassium channel opener with bladder-relaxant properties.
• Protection of pirfenidone against an early phase of oleic acid-induced acute lung injury in rats.
• Cancer gene expression database (CGED): a database for gene expression profiling with accompanying clinical information of human cancer tissues.
• Antitumor immunization of head and neck squamous cell carcinoma patients with a virus-modified autologous tumor cell vaccine.
• Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.
• Farnesyltransferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration.
• Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial.
• Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
• Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.
• Discovery of N-(2-chl